AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.
The company also announced a collaboration and license option agreement with ADARx Pharmaceuticals to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology, and oncology.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
